Inactive Instrument

Fibrocell Science, Inc.

Equities

US3157214079

Biotechnology & Medical Research

Douglas J. Swirsky Joins Fibrocell Science, Inc. Board

March 05, 2013 at 08:00 am EST

Fibrocell Science, Inc. announced that Douglas J. Swirsky, CPA, CFA, joined its Board of Directors. Since 2006, Mr. Swirsky has served as Senior Vice President, Chief Financial Officer, Treasurer and Corporate Secretary of GenVec, Inc. Mr. Swirsky previously held investment banking positions at UBS, PaineWebber, Morgan Stanley, and Legg Mason. Prior to joining GenVec, Mr. Swirsky was with Stifel Nicolaus where he served as a Managing Director and the Head of Life Sciences Investment Banking.

His experience also includes positions in public accounting and consulting.

Latest news about Fibrocell Science, Inc.

Fibrocell Science, Inc.(NasdaqGM:FCSC) dropped from S&P TMI Index	19-12-16	CI
Fibrocell Science, Inc.(NasdaqGM:FCSC) dropped from NASDAQ Composite Index	19-12-13	CI
Castle Creek Pharmaceutical Holdings, Inc. completed the acquisition of Fibrocell Science, Inc..	19-12-12	CI
Fibrocell Science, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-14	CI
Castle Creek Pharmaceutical Holdings, Inc. entered into a definitive agreement to acquire Fibrocell Science, Inc. for $63.3 million.	19-09-11	CI
Fibrocell Science, Inc Appoints Sean D. Buckley as Chief Financial Officer	19-08-22	CI
Fibrocell Science, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-14	CI
Fibrocell Science, Inc. Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB	19-05-29	CI
Fibrocell Science, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-15	CI
Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy	19-04-15	CI
Fibrocell Science, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018	19-03-27	CI
Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007	19-03-27	CI
Fibrocell Science, Inc. Auditor Raises 'Going Concern' Doubt	19-03-26	CI
Fibrocell Science, Inc. announced that it has received $0.9 million in funding from EB Research Partnership, Inc., Endowment Arm, Epidermolysis Bullosa Medical Research Foundation, Endowment Arm	18-12-10	CI
Fibrocell Science, Inc. announced that it expects to receive $0.9 million in funding from EB Research Partnership, Inc., Endowment Arm, Epidermolysis Bullosa Medical Research Foundation, Endowment Arm	18-12-06	CI
Fibrocell Science, Inc. Reports Consolidated Unaudited Earnings Results for the Nine Months Ended September 30, 2018	18-11-13	CI
Fibrocell Science, Inc. Receives Guidance from FDA on Phase 3 Clinical Trial Design for FCX-007	18-10-25	CI
Fibrocell Science, Inc. Announces U.S. Food and Drug Administration Granted Fast Track Designation to FCX-013	18-09-05	CI
Fibrocell Science, Inc. Announces Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2018; Expects to Enroll A Total of Six Patients Ages Seven and Older by the End of the Third Quarter of 2018	18-08-09	CI
Fibrocell Science, Inc. announced that it has received $0.119769 million in funding	18-07-04	CI
Fibrocell Science, Inc. announced that it expects to receive $0.119769 million in funding	18-07-01	CI
Fibrocell Science, Inc. Appoints Sean D. Buckley as Vice President of Business Administration and Corporate Secretary	18-06-22	CI
Fibrocell Science, Inc. announced that it has received $0.191084 million in funding	18-05-30	CI
Fibrocell Science, Inc. announced that it expects to receive $0.191084 million in funding	18-05-28	CI
Fibrocell Science, Inc. Provides an Update on Interim Results and Progress of its Phase 1/2 Clinical Trial of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa	18-05-21	CI

Chart Fibrocell Science, Inc.

Duration

Period

More charts

Company Profile

Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+33.37%	49.46B
IQVIA HOLDINGS INC.	+1.55%	42.58B
LONZA GROUP AG	+49.11%	42.49B
CELLTRION, INC.	-4.22%	29.09B
ICON PUBLIC LIMITED COMPANY	+11.57%	26.61B
ALNYLAM PHARMACEUTICALS, INC.	-21.00%	18.64B
BIO-TECHNE CORPORATION	+7.36%	13.16B
MEDPACE HOLDINGS, INC.	+28.30%	12.55B
UNITED THERAPEUTICS CORPORATION	+23.80%	12.1B

Other Biotechnology & Medical Research